Business | Press Trust of India | Thursday October 29, 2015
Glenmark Pharmaceuticals' licensing deal with Sanofi for a new molecule - Vatelizumab - aimed at treating multiple sclerosis (MS) has ended with the French drug major deciding against pursuing it as the molecule did not meet the primary efficacy endpoint.
www.ndtv.com/business